ClinicalTrials.gg
Not yet recruitingNCT07649200SNH-118110Updated Jun 16, 2026

Study of SNH-118110 in Advanced Solid Tumors

A Phase 1 interventional study of SNH-118110 Soft Capsules in Solid Tumors, sponsored by ScinnoHub Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-16.

Primary conditionnone(registry's first term: Carcinoma, Medullary)Many cancersIs this wrong?The study is open to many cancers (its listed conditions name solid tumors in general), and its title does not single out Carcinoma, Medullary, so we do not take that as its main condition. It is not compared with other studies by condition.

Sponsored by ScinnoHub Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
240
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a multicenter, open-label, Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of SNH-118110 administered orally. The study consists of a dose-escalation phase and a dose-expansion phase.

Read the detailed description

This first-in-human, open-label, multicenter Phase I study is designed to assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of SNH-118110 administered orally. The study comprises two sequential parts: a dose-escalation phase to identify the maximum tolerated dose (MTD) or maximum administered dose (MAD), followed by a dose-expansion phase to further evaluate safety and anti-tumor activity. The primary endpoints include safety, MTD, and/or MAD.

02

Conditions studied

  • Solid Tumors

Browse trials for

Keywords

  • Advanced Solid Tumors
  • Medullary Thyroid Cancer
  • Non-Small Cell Lung Cancer
03

In context

Lead sponsor

ScinnoHub Pharmaceutical Co., Ltd. is the lead sponsor of 6 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to understand and voluntarily sign an form (ICF) prior to any study related procedures.
  • Age ≥ 18 years at the time of signing the ICF.
  • or cytologically confirmed diagnosis of advanced solid tumors, with the following additional requirements:

Dose-escalation phase: Patients with advanced solid tumors harboring a RET gene alteration who have failed standard therapy or are intolerant to standard therapy.

Dose-expansion phase:

Cohort 1: Locally advanced or NSCLC with RET gene fusion who have progressed after at least one , which must include a RET inhibitor.

Cohort 2: Treatment-naïve patients with locally advanced or metastatic NSCLC harboring a RET gene fusion.

Cohort 3: Other advanced solid tumors harboring RET gene alterations.

  • At least one measurable target lesion according to version 1.1.
  • Documentation of a RET fusion or other activating RET gene alteration (based on a local or central laboratory report).
  • (ECOG) performance status of 0 or 1, with no deterioration within the 2 weeks prior to the first dose of study drug.
  • of at least 3 months.

Exclusion criteria

Exclusion Criteria:

  • Presence of other known oncogenic driver mutations.
  • Prior anti-tumor therapy within specified prior to first dose (e.g., small molecules, biologics, radiotherapy, major surgery), or failure to recover from toxicities.
  • Clinically significant uncontrolled or active conditions, including but not limited to:

Inadequate bone marrow, hepatic, or renal function. Significant cardiovascular disease (e.g., uncontrolled hypertension, prolonged , poor , recent thromboembolic events).

Active or uncontrolled infections, bleeding diathesis, or significant pleural/abdominal/pericardial effusion requiring intervention.

Central nervous system unless stable and asymptomatic off .

  • Conditions affecting oral drug absorption or gastrointestinal function.
  • History of severe allergic reactions to similar agents.
  • Pregnant or lactating women, or patients with serious concurrent medical or psychiatric conditions that would compromise safety or study compliance.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    SNH-118110

    Dose escalation: Multiple doses of SNH-118110 Dose expansion: MTD/MAD/recommended expansion dose

    Drug: SNH-118110 Soft Capsules

Interventions

  • DrugSNH-118110 Soft Capsules

    Participants will continue treatment until progression of disease or the end of the study.

06

What researchers measure

Primary outcomes

  1. Safety evaluation

    Incidence and severity of adverse events (AEs) and serious adverse events (SAEs).

    Time frame: Up to approximately 2 years

  2. Maximum tolerated dose (MTD) or maximum administered dose (MAD)

    Determination of the MTD or MAD of oral SNH-118110 by the number of participants who experience a dose limiting toxicity (DLT)

    Time frame: Cycle 1 (up to 21 days)

Secondary outcomes

  1. The maximum concentration (Cmax)

    Cmax of SNH-118110

    Time frame: Cycle 1 day 1 through cycle 2 day 1 (cycle= 21 days)

  2. Time of the maximum concentration (Tmax)

    Tmax of SNH-118110

    Time frame: Cycle 1 day 1 through cycle 2 day 1 (cycle= 21 days)

  3. Area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration (AUC0-t)

    AUC0-t of SNH-118110

    Time frame: Cycle 1 day 1 through cycle 2 day 1 (cycle= 21 days)

  4. Elimination half-life (t1/2)

    T1/2 of SNH-118110

    Time frame: Cycle 1 day 1 through cycle 2 day 1 (cycle= 21 days)

  5. Objective response rate (ORR)

    ORR of SNH-118110 evaluated by investigators per RECIST v1.1

    Time frame: Up to approximately 2 years

  6. Disease control rate (DCR)

    DCR of SNH-118110 evaluated by investigators per RECIST v1.1

    Time frame: Up to approximately 2 years

  7. Duration of response (DoR)

    DoR of SNH-118110 evaluated by investigators per RECIST v1.1

    Time frame: Up to approximately 2 years

  8. Progression-free survival (PFS)

    PFS of SNH-118110 evaluated by investigators per RECIST v1.1

    Time frame: Up to approximately 2 years

  9. Overall survival (OS)

    Overall survival (OS)

    Time frame: Up to approximately 2 years

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Jun 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2026
First posted
Jun 16, 2026
StartEst.
Jun 26, 2026
Primary completionEst.
Jun 26, 2027
CompletionEst.
Jun 26, 2029
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07649200
Lead sponsor
ScinnoHub Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Jun 16, 2026
Start date
Jun 26, 2026 (estimated)
Primary completion
Jun 26, 2027 (estimated)
Completion
Jun 26, 2029 (estimated)
Last update
Jun 16, 2026

Study contacts

Caicun Zhou, MD
Contact
CAICUNZHOUDR@TONGJI.EDU.CN
86 021-58822171

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion